Literature DB >> 21884442

Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea.

Taekyu Lim1, Jeeyun Lee, Jae J Kim, Jong Kyun Lee, Kyu Taek Lee, Young Ho Kim, Kwang-Won Kim, Sung Kim, Tae Sung Sohn, Dong Wook Choi, Seong Ho Choi, Ho-Kyung Chun, Woo Young Lee, Kyoung-Mee Kim, Kee-Taek Jang, Young Suk Park.   

Abstract

AIM: We studied to identify the clinicopathological features, treatment outcome, and prognostic factors for patients with gastrointestinal and hepatopancreaticobiliary neuroendocrine tumor (NET).
METHOD: Between February 2001 and May 2006, a total of 470 patients were diagnosed with NET arising from the gastrointestinal tract, pancreas, and hepatobiliary system. The retrospective patient cohort was obtained and analyzed.
RESULTS: The male to female ratio was 1.5:1, and the median age was 55 years (range, 16-81). The most common primary site was the rectum (55.8%). Overall 29 (6.2%) originated from the hepatobiliary system. At initial presentation, 60 patients (12.8%) showed distant metastases. Curative surgery or endoscopic resection was performed in 401 patients. Histopathological distributions were as follows: well differentiated tumor (82.1%), well differentiated carcinoma (10.2%) and poorly differentiated carcinoma (7.7%). The frequency of the poorly differentiated type was somewhat higher in the hepatobiliary system than in the pancreas and gastrointestinal tract (44.8, 15.4 and 2.8%, respectively, P < 0.05). The estimated 5-year overall survival rate for all patients was 89.6%. Multivariate analysis showed that distant metastases (P = 0.018), origin from the hepatobiliary system (P < 0.001) and poorly differentiated neuroendocrine carcinoma (P < 0.001) were independent predictors for poor survival outcome.
CONCLUSION: Patients with locoregional NET had a favorable long-term survival after curative resection. Distant metastases, hepatobiliary localization and a poor degree of tumor cell differentiation were poor prognostic factors. Further investigational approaches for treatment of advanced disease are needed.
© 2011 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21884442     DOI: 10.1111/j.1743-7563.2011.01423.x

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  13 in total

1.  Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of China.

Authors:  Xuelong Jiao; Yujun Li; Hongyan Wang; Shanglong Liu; Dongfeng Zhang; Yanbing Zhou
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

2.  Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms.

Authors:  Zhiqiang Wang; Wenliang Li; Tianxing Chen; Jun Yang; Lilin Luo; Lianyu Zhang; Baocun Sun; Rui Liang
Journal:  Exp Ther Med       Date:  2015-07-13       Impact factor: 2.447

3.  Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.

Authors:  Tetsuhide Ito; Hisato Igarashi; Kazuhiko Nakamura; Hironobu Sasano; Takuji Okusaka; Koji Takano; Izumi Komoto; Masao Tanaka; Masayuki Imamura; Robert T Jensen; Ryoichi Takayanagi; Akira Shimatsu
Journal:  J Gastroenterol       Date:  2014-02-06       Impact factor: 7.527

4.  The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.

Authors:  Seung Tae Kim; Sang Yun Ha; Jeeyun Lee; Sung No Hong; Dong Kyung Chang; Young Ho Kim; Yoon Ah Park; Jung Wook Huh; Yong Beom Cho; Seong Hyeon Yun; Woo Yong Lee; Hee Cheol Kim; Young Suk Park
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

5.  Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis.

Authors:  Doris T Chan; Andrea O Y Luk; W Y So; Alice P S Kong; Francis C C Chow; Ronald C W Ma; Anthony W I Lo
Journal:  BMC Endocr Disord       Date:  2016-02-24       Impact factor: 2.763

6.  Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.

Authors:  Meng Zhang; Ping Zhao; Xiaodan Shi; Ahong Zhao; Lianfeng Zhang; Lin Zhou
Journal:  BMC Endocr Disord       Date:  2017-07-13       Impact factor: 2.763

7.  Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.

Authors:  Yuhong Wang; Wei Wang; Kaizhou Jin; Cheng Fang; Yuan Lin; Ling Xue; Shiting Feng; Zhiwei Zhou; Chenghao Shao; Minhu Chen; Xianjun Yu; Jie Chen
Journal:  Oncol Lett       Date:  2017-01-11       Impact factor: 2.967

8.  Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.

Authors:  Yu-Hong Wang; Yuan Lin; Ling Xue; Jin-Hui Wang; Min-Hu Chen; Jie Chen
Journal:  BMC Endocr Disord       Date:  2012-11-29       Impact factor: 2.763

9.  Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours.

Authors:  H K Ahn; J Y Choi; K-M Kim; H Kim; S-H Choi; S H Park; J O Park; H Y Lim; W K Kang; J Lee; Y S Park
Journal:  Br J Cancer       Date:  2013-08-29       Impact factor: 7.640

10.  Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.

Authors:  Xianbin Zhang; Li Ma; Haidong Bao; Jing Zhang; Zhongyu Wang; Peng Gong
Journal:  BMC Endocr Disord       Date:  2014-07-08       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.